Pomalyst

Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit
Reuters
Thu, 09/7/23 - 10:57 pm
Bristol Myers Squibb
Celgene
patents
legal
Pomalyst
BMS publishes 'modest' multiple myeloma survival data on heir to Revlimid, Pomalyst
Fierce Biotech
Thu, 08/31/23 - 10:55 am
Bristol Myers Squibb
Revlimid
Pomalyst
Multiple Myeloma
mezigdomide
Bristol Myers snags Pomalyst green light in rare AIDS-related skin lesions
Fierce Pharma
Sat, 05/16/20 - 11:58 am
Bristol-Myers Squibb
Pomalyst
AIDS
FDA
Kaposi's Sarcoma
Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma
Pharmaceutical Business Review
Tue, 05/14/19 - 09:23 am
Celgene
Pomalyst
breakthrough therapies
Kaposi's Sarcoma
Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myeloma
Fierce Pharma
Thu, 11/8/18 - 09:41 am
Bristol-Myers Squibb
AbbVie
Empliciti
FDA
Multiple Myeloma
Celgene
Pomalyst
Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review
Yahoo/Zacks.com
Fri, 08/24/18 - 11:08 am
Bristol-Myers Squibb
Empliciti
Celgene
Pomalyst
Multiple Myeloma
With Revlimid and Pomalyst price increases, could Celgene be next on Trump’s to-call list?
Fierce Pharma
Thu, 07/12/18 - 06:30 pm
Pfizer
Celgene
drug pricing
Donald Trump
Revlimid
Pomalyst
Looking to grow blockbuster Pomalyst franchise, Celgene declares a win for multiple myeloma triplet in pivotal PhIII
Endpoints
Tue, 02/6/18 - 09:50 am
Celgene
Pomalyst
Multiple Myeloma
clinical trials
Celgene takes its most aggressive price hikes yet on Revlimid, Pomalyst: analyst
Fierce Pharma
Tue, 10/24/17 - 05:33 pm
Celgene
Revlimid
Pomalyst
drug pricing
5 Reasons Celgene Will Be a Top Biotech Stock for the Next Decade
Motley Fool
Thu, 03/9/17 - 09:54 am
Celgene
Revlimid
Pomalyst
Abraxane
Otezla
Celgene's Fastest-Growing Drugs
Motley Fool
Thu, 01/26/17 - 07:00 pm
Celgene
Otezla
Pomalyst
What's Next For Celgene
Motley Fool
Wed, 01/11/17 - 10:13 am
Celgene
JPMHC 2017
Otezla
ozanimod
Revlimid
Pomalyst
New Merck Study Shows Combos Will Drive Celgene Growth: RBC
Barron's
Fri, 10/16/15 - 07:44 pm
Merck
Celgene
Pomalyst
The top 10 most expensive drugs of 2013
Fierce Pharma
Tue, 10/14/14 - 10:05 am
drug pricing
Soliris
Alexion
Naglazyme
Biomarin
Kalydeco
Vertex
Cinryze
Shire
Sprycel
Bristol-Myers Squibb
Pomalyst
Celgene
Xyrem
Jazz Pharmaceuticals
Erbitux
Merck KGaA
Revlimid
Questcor
Mallinckrodt
H.P. Acthar Gel
Analysis of FDA side-effect reports flags Sanofi, Celgene meds
Fierce Pharma
Tue, 01/28/14 - 11:37 am
Celegene
FDA
Sanofi
side effects
Pomalyst
Tecfidera
Biogen Idec
Aubagio
Celgene's New Multiple Myeloma Drug Is Beating Amgen
TheStreet.com
Thu, 10/24/13 - 09:59 am
Celgene
Multiple Myeloma
Amgen
Kyprolis
Pomalyst
Celgene's Multiple Myeloma Powerhouse
Motley Fool
Thu, 08/22/13 - 11:21 am
Multiple Myeloma
Celgene
Thalomid
Revlimid
Pomalyst
Celgene at ASCO: Ho-Hum, Ho-Hum, and Hmmm
Motley Fool
Wed, 06/5/13 - 12:24 pm
Celgene
ASCO
Pomalyst
Abraxane
Revlimid
Celgene's Rich Pipeline Offers Growth
Seeking Alpha
Thu, 04/4/13 - 09:13 am
Celgene
Eli Lilly
Bristol-Myers Squibb
Roche
ONYX Pharmaceuticals
Pomalyst
Revlimid
Abraxane
Celgene And The Race To Cure Multiple Myeloma
Seeking Alpha
Sat, 02/16/13 - 11:23 am
Celgene
Multiple Myeloma
Pomalyst

Pages